Luka Stanisavljevic
Overview
Explore the profile of Luka Stanisavljevic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
112
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nieder C, Haukland E, Stanisavljevic L, Mannsaker B
Anticancer Res
. 2025 Mar;
45(3):1149-1158.
PMID: 40037873
Background/aim: The aim was to analyze patterns of care, , fractionation of radiotherapy and treatment completion, and prognostic factors for survival in patients irradiated for bone metastases who had excellent...
2.
Nieder C, Stanisavljevic L, Dalhaug A, Haukland E
Cancer Diagn Progn
. 2025 Mar;
5(2):138-145.
PMID: 40034952
Background/aim: Several recent studies, varying in design and the number of baseline parameters analyzed, suggest that a lower body mass index (BMI) is associated with shorter survival in men beginning...
3.
Nieder C, Aanes S, Stanisavljevic L, Mannsaker B, Haukland E
Oncol Res Treat
. 2024 Dec;
48(3):82-91.
PMID: 39631375
Introduction: Immune checkpoint inhibitors (ICIs) are now standard of care in systemic treatment for many types of metastatic cancer, often together with cytotoxic chemotherapy. Monitoring of treatment efficacy against clinical...
4.
Nieder C, Haukland E, Stanisavljevic L, Mannsaker B
Radiat Oncol
. 2024 Nov;
19(1):151.
PMID: 39487535
Background: Complex high-precision radiotherapy, such as stereotactic body radiotherapy (SBRT), should only be offered to patients with sufficiently long survival. In the context of bone metastases radiotherapy, low rates of...
5.
Nieder C, Aanes S, Stanisavljevic L, Mannsaker B, Haukland E
J Neurooncol
. 2024 Oct;
171(1):139-154.
PMID: 39352620
Purpose: The study's purpose was to analyze return to work and other long-term outcomes in younger patients with newly diagnosed brain metastases, treated before they reached legal retirement age, i.e....
6.
Nieder C, Aanes S, Stanisavljevic L, Mannsaker B
Discov Oncol
. 2024 Sep;
15(1):495.
PMID: 39331216
Background: This retrospective study analyzed the incidence of subsequent brain metastases after palliative radiotherapy or chemoradiation in patients with stage II/III non-small cell lung cancer (NSCLC). Risk factors for brain...
7.
Nieder C, Stanisavljevic L, Mannsaker B
Anticancer Res
. 2024 May;
44(6):2637-2643.
PMID: 38821600
Background/aim: Blood tests, such as those included in the validated LabBM score (laboratory parameters in patients with brain metastases) predict survival after treatment of brain metastases. The model incorporates five...
8.
Nieder C, Stanisavljevic L, Dalhaug A, Haukland E
Contemp Oncol (Pozn)
. 2024 May;
28(1):31-36.
PMID: 38800536
Introduction: The aim of this study was to evaluate overall survival of men who received systemic therapy with docetaxel for metastatic castration- resistant prostate cancer (MCRPC) in rural Nordland County,...
9.
Nieder C, Stanisavljevic L, Haukland E
Cancer Diagn Progn
. 2024 May;
4(3):250-255.
PMID: 38707739
Background/aim: Numerous new treatment options have been approved for metastatic renal cell carcinoma (mRCC) in the last decade. Nevertheless, not all patients receive systemic therapy. Certain patients present with very...
10.
Nieder C, Stanisavljevic L, Mannsaker B, Haukland E
Anticancer Res
. 2023 Jun;
43(7):3167-3172.
PMID: 37351967
Background/aim: The aim of this study was to analyze the validity of a unifying prognostic model, originally developed by Kowalchuk et al., because relevant variations in clinical practice and observed...